| Basics |
REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
|
| IPO Date: |
September 17, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$454.95M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.80 | 2.87%
|
| Avg Daily Range (30 D): |
$0.41 | 4.93%
|
| Avg Daily Range (90 D): |
$0.30 | 4.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.36M |
| Avg Daily Volume (30 D): |
1M |
| Avg Daily Volume (90 D): |
.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
82 |
| Avg Trade Size (Sh.) (90 D): |
79 |
| Institutional Trades |
| Total Inst.Trades: |
3,176 |
| Avg Inst. Trade: |
$1.97M |
| Avg Inst. Trade (30 D): |
$1.05M |
| Avg Inst. Trade (90 D): |
$1.13M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.27M |
| Avg Closing Trade (30 D): |
$.8M |
| Avg Closing Trade (90 D): |
$1.01M |
| Avg Closing Volume: |
81.45K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-3.1
|
$.12
|
$-1
|
|
Diluted EPS
|
$-3.1
|
$.12
|
$-1
|
|
Revenue
|
$ 156.72M
|
$ 89.01M
|
$ 21.21M
|
|
Gross Profit
|
$
|
$
|
$ 14.9M
|
|
Net Income / Loss
|
$ -157.69M
|
$ 6.08M
|
$ -51.19M
|
|
Operating Income / Loss
|
$ -157.36M
|
$ 12.13M
|
$ -51.37M
|
|
Cost of Revenue
|
$
|
$
|
$ 6.32M
|
|
Net Cash Flow
|
$ 17.13M
|
$ 72.58M
|
$ .91M
|
|
PE Ratio
|
|
|
|
|
